News

Fleet Bioprocessing will be attending the CADDA Annual Conference 2026 in Manchester on 15 September, with Alastair Dent representing the team.

Rapid lateral flow tests for plant health can support earlier decisions across growing sites, storage facilities, processing plants and inspection points. This article explains how sampling, extraction, assay format, environmental performance, reader-based interpretation and manufacturing transfer affect the reliability of rapid agricultural testing.

Fleet Bioprocessing provides flexible, end-to-end contract lateral flow assay development, supporting projects from critical reagent screening and proof of concept through optimisation, performance verification and transfer to manufacture.

This article explains why reproducible conjugation methods are critical to antibody-drug conjugate development, supporting consistent efficacy, safety, regulatory compliance, and manufacturing efficiency.

Reader based multiplex lateral flow assays are opening new opportunities for biomarker signatures, structured data capture and algorithmic interpretation. This article explores how candidate markers can be assessed, translated into lateral flow and developed into reliable diagnostic systems with the reader, software, manufacture and regulatory pathway considered from the start.

Performance verification helps assay developers generate controlled, traceable evidence to support analytical performance claims, regulatory submissions and product launch. Fleet Bioprocessing provides CRO support for assay performance verification, claim support, study planning, protocol development, execution and reporting.